AXIONOVA SIGNAL identifies developments that may meaningfully change how we understand health, science, technology and human performance.
Each signal is examined against the available evidence, placed in context, and written to explain not only what happened, but why it matters, what the evidence actually supports, and what remains uncertain.
Hi, I am ALETHA. I help you understand your data and prepare it for your practitioner. I do not make clinical decisions; your practitioner does.
AXIONOVA™ runs on two layers. ALETHRA™ governs the system. ALETHA™ guides the experience. A licensed physician authorizes every clinical outcome.
Published intelligence, ordered by release date.
The FDA is seeking input on how to assess drugs and biologics for very small rare-disease populations. Its new initiative could shape future review practices, but it has not changed approval requirements.
Read SIGNALBioNTech says BNT113 plus pembrolizumab missed AHEAD-MERIT’s progression-free-survival endpoint against pembrolizumab alone. The trial continues to assess whether the combination improves overall survival.
Read SIGNALPar Health recalled 22 U.S.-distributed lots of argatroban injection after finding particles in certain lots. It reported no related adverse events when it announced the recall.
Read SIGNALA study of records from 52,236 adults maps when cancer-associated weight-loss episodes occur and tests a risk model in an independent cohort of 5,785 patients. It does not show that using predictions improves care.
Read SIGNALWHO’s new pandemic-hub strategy aims for every country to detect and understand emerging health threats within 24 hours by 2030. Existing surveillance networks provide a foundation, but the deadline remains an ambition, not a demonstrated capability.
Read SIGNAL
